Claims for Patent: 10,793,911
✉ Email this page to a colleague
Summary for Patent: 10,793,911
Title: | Host DNA as a biomarker of Crohn\'s disease |
Abstract: | The invention relates to methods of analysing a sample from a subject having or suspected of having Crohn\'s disease for the abundance of the subject\'s nucleic acid (e.g., DNA) in the sample. The invention also relates to methods for measuring abundance of nucleic acid (e.g., DNA) in stool from a human subject having or suspected of having Crohn\'s Disease (CD). In various embodiments, an in vitro method includes analysing the relative abundance of the host (human) DNA in said sample of stool or nucleic acid extracted or isolated from a stool sample from the host (human); determining the relative abundance of the host (human\'s) DNA in the sample; and associating the abundance of the host (human) DNA with the host (human) providing the stool sample, or the host (human) providing the stool sample from which the nucleic acid was extracted. |
Inventor(s): | Cervino; Alessandra Cristina L (Paris, FR) |
Assignee: | ENTEROME (Paris, FR) |
Application Number: | 15/877,336 |
Patent Claims: | 1. A method for treating a subject suffering from Crohn's disease (CD), comprising: providing a stool sample from a subject suffering from Crohn's disease, wherein the stool
sample comprises subject DNA; performing an assay to quantify the relative abundance of subject DNA in the sample; and administering a CD treatment to the subject when the relative abundance of the subject DNA is above 1%.
2. The method of claim 1, further comprising: preparing protein from the stool sample; and measuring a level of calprotectin protein in the stool sample. 3. The method of claim 2, further comprising determining if the calprotectin protein level is higher than a reference level. 4. The method of claim 3, wherein the reference level is 150 .mu.g/mL of caiprotectin protein. 5. The method of claim 1, wherein the method does not comprise an endoscopic evaluation of the subject. 6. The method of claim 1, wherein the treatment is selected from the group consisting of azathioprine, mesalamine, abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, natalizumab, corticosteroids, cyclosporine, methotrexate, tacrolimus, Anti-JAK (tofacitinib), anti-integrins (Vedolizumab, rhuMAb Beta7, MAdCAM-1 Antagonist), and Anti IL12/IL23 (Ustekinumab, ABT874). 7. The method of claim 1, wherein the treatment is a diet of different caloric restriction intensities and macronutrient composition. |
Details for Patent 10,793,911
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2035-01-30 |
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2035-01-30 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2035-01-30 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2035-01-30 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2035-01-30 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2035-01-30 |
Immunex Corporation | ENBREL MINI | etanercept | Injection | 103795 | 09/14/2017 | ⤷ Try a Trial | 2035-01-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.